News | Radiation Therapy | February 13, 2020

ASTRO Awarded Contract from VA to Develop Measures on Quality of Radiation Therapy Services

The American Society for Radiation Oncology (ASTRO) has been awarded a new one-year contract from the U.S. Department of Veterans Affairs (VA) to develop quality indicators (QI) for radiation treatments provided to veterans with head and neck, breast and gastrointestinal cancers

February 13, 2020 — The American Society for Radiation Oncology (ASTRO) has been awarded a new one-year contract from the U.S. Department of Veterans Affairs (VA) to develop quality indicators (QI) for radiation treatments provided to veterans with head and neck, breast and gastrointestinal cancers.

“This pioneering effort leverages evidence-based guidelines and the consensus of medical experts in a new and powerful way to optimize care for military veterans,” said Theodore L. DeWeese, M.D., FASTRO, Chair of the ASTRO Board of Directors. “VA’s leadership in this area is impressive. ASTRO is honored to work with VA in this effort to promote high quality care to our nation’s veterans.”

More than 16,000 veterans receive radiation oncology care through 40 VA clinics nationwide each year. The new metrics will support the VA Radiation Oncology Quality Surveillance program (VA-ROQS), which was established to standardize and improve services at these facilities. Recently, ASTRO partnered with VA to establish QI for lung and prostate cancers forming the evidence basis for the VA-ROQS program.

The goal of VA-ROQS is to combine information technology with clinical expertise to provide physicians with real-time, evidence-based feedback on areas of quality-related performance. Data gathered from these QI, such as radiation dosing or treatment delivery, can then be used by VA-ROQS for quality assessments that show how an individual case scores against national benchmarks and other VA practitioners. The VA-ROQS program allows VA physicians to pinpoint areas for improvement and make meaningful adjustments in their patient care.

ASTRO previously worked with VA and Washington University on the national Radiation Oncology Practice Assessment (ROPA) program. ROPA, the pilot study for VA-ROQS, created the methodology and IT infrastructure while providing comprehensive QI for VA radiation oncologists treating patients with prostate or lung cancers. From 2016 to 2018, the program evaluated more than 1,500 patient cases across the 40 VA facilities, and a recent analysis indicates that from the outset more than 80% of these cases met or exceeded quality standards.

For more information: www.astro.org

Related Content

Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
March 16, 2020 — The Ann...